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Abstract
 .The ether lipid, 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine ET-18-OCH , has anticancer activity, but it3
has serious side-effects, including hemolysis, which prevent its optimal use. We surmised if ET-18-OCH could be stably3
associated with liposomes, less free ET-18-OCH would be available for lytic interaction with red cells. Liposome3
composition variables investigated included acyl chain saturation, phospholipid head group and mole ratio of Chol and
ET-18-OCH . It was found that attenuation of hemolysis was strongly liposome composition dependent. Some ET-18-OCH3 3
liposome compositions were minimally hemolytic. For example, whereas the HI drug concentration required to cause 5%5
. human red cell lysis was 5–6 mM for free ET-18-OCH , it was approximately 250 mM for DOPC dioleoylphosphatidyl-3
.  .  .  .choline :Chol cholesterol :DOPE-GA glutaric acid derivatized DOPE :ET-18-OCH , 4:3:1:2 and 640 mM for DOPE3
 .  .  .dioleyolphosphatidylethanolamine :Chol:DOPE-GA:ET-18-OCH 4:3:1:2 liposomes. Efflux of carboxyfluorescein CF3
 .from liposomes and Langmuir trough determinations of mean molecular area of lipids in monolayers MMAM were used
as indicators of membrane packing and stability. Incorporation of ET-18-OCH in liposomes reduced the MMAM.3
Reduction in CF permeation was correlated with reduction in hemolysis. The most stable liposomes included components,
such as cholesterol, DOPC and DOPE, which have complementary shapes to ET-18-OCH . q 1997 Elsevier Science B.V.3
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1. Introduction
The ether lipid, 1-O-octadecyl-2-O-methyl-sn-
 .glycero-3-phosphocholine ET-18-OCH is selec-3
tively cytotoxic to cancer cells compared to normal
w xcells in vitro 1 and inhibits the growth of murine
w xand human tumors in experimental systems 2,3 . Its
) Corresponding author. Fax: q1-609-5208250.
clinical use by the i.v. route has been hampered,
however, by gastrointestinal and other toxicities, in-
w xcluding hemolysis 2–4 .
We postulated that stable association of ET-18-
OCH with liposomes would greatly reduce its avail-3
ability to interact with red cells, thereby reducing
hemolysis and perhaps other unwanted side effects. It
has been shown that the in vivo toxicity of various
drugs can be markedly reduced by stably associating
w xthem with liposomes 5 . Several liposome formula-
0005-2736r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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w xtions are in advanced clinical trials for cancer 6 and
w xinfectious diseases 7 and some have received mar-
w xketing approval 8 . Although ET-18-OCH has been3
w xincorporated in liposomes previously 9 , no system-
atic study of how it interacts with various lipid
compositions has been reported. Recently a 1:1.5
ET-18-OCH :Chol assembly was shown to have quite3
w xfavorable packing properties 10 . Here, liposome
formulations of ET-18-OCH and cholesterol plus3
other components varying with respect to phospho-
lipid saturation, head group and charge were com-
pared using a hemolysis assay as an indicator of the
availability of ET-18-OCH to interact with red cell3
membranes. In order to more fully understand the
basis for the observed effects, the permeation of
carboxyfluorescein from ET-18-OCH liposomes and3
the effect of ET-18-OCH on lipid mean molecular3
surface area was also investigated for some formula-
tions.
2. Materials and methods
2.1. Chemicals
1-O-Octadecyl-2-O-methyl-sn-glycero-3-phos-
 .phocholine ET-18-OCH , Edelfosine , DOPC,3
 .DOPE, egg phosphatidylcholine EPC , distearoyl
 .phosphatidylcholine DSPC , glutaric acid derivatized
 .dipalmitoylphosphatidylethanolamine DPPE-GA ,
glutaric acid derivatized palmitoyloleylphos-
 .phatidylethanolamine POPE-GA , dipalmitoylphos-
 .phatidylglycerol DPPG and DOPE-GA were ob-
 .tained from Avanti Polar Lipids Alabaster, Alabama
except where otherwise noted. Chol was purchased
from the Sigma Chemical Company, USA. Phosphate
 .buffered saline PBS was purchased from Gibco
 .BRL Life Technologies Grand Island, New York .
Human serum was obtained from Sigma Chemical
 .St. Louis, MO . All lipids and reagents were of the
highest purity available.
2.2. Preparation of liposomes
ET-18-OCH liposomes and non-ET-18-OCH -3 3
 .containing sham liposomes were prepared by the
w xsolvent evaporation method 11 . ET-18-OCH and3
lipids were dissolved in chloroform to give different
molar lipid ratios of phospholipid:Chol:ET-18-OCH3
with or without 10 mol% DPPE-GA, POPE-GA or
DOPE-GA. The compositions investigated are given
in Table 1. The organic solvent was initially removed
by rotary evaporation at 458C, using 500 ml round
bottom flasks. The thin film, containing up to 120 mg
lipid, was then dried for at least 18 h at less than 1
 .Torr Edwards Pump, Crawley, Sussex, England .
The film was hydrated with PBS for 1 h above the
 .transition temperature T of the lipid, forming lipo-m
some suspensions at 5–10 mgrml ET-18-OCH . In3
initial studies the liposomes were then extruded di-
rectly. In later studies the liposomes were frozen in
liquid nitrogen and thawed at 408C for 10 cycles and
then extruded 10 times through 0.1 mm double
stacked Nucleopore filters using an extruder device
 .Lipex Biomembranes Vancouver, BC, Canada and
were examined by light microscopy to check for
possible aggregation. Some preparations were ana-
lyzed for chemical composition by reverse phase
 .HPLC Inertsil ODS2 150=4.6 mm column with an
evaporative-light scattering detector using 4% water
in methanol as the mobile phase. The size distribu-
tions of liposome preparations were determined using
a Nicomp Model 370 Particle Sizer system Santa
.Barbara, California .
2.3. Electron microscopy
For freeze-fracture electron microscopy, 1–3 ml of
sample without cryoprotectant was placed between a
pair of Balzers copper double replicating holders and
w xfrozen from room temperature in liquid propane 12 .
A Balzers BAF 400 freeze-fracture device was used.
Replicas were cleaned overnight in 5% hypochlorite
 .commercial bleach , washed in distilled water,
mounted on 300 mesh grids and viewed with a
Philips 300 TEM.
2.4. Hemolysis
 .Lysis of human red blood cells RBC by free or
ET-18-OCH -liposomes was quantitated by3
w xhemoglobin release into buffer 13 . Various concen-
 .trations 3 mM–2 mM of free and ET-18-OCH -3
liposomal, or ET-18-OCH free liposomes 1:1 vrv,3
.blood:formulation, serially diluted were incubated
 .with 4% RBC washed in PBS, 3= at 378C for 20
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h. The release of hemoglobin from an equal number
of RBC by hypotonic lysis in water was taken as
100% positive control. Incubation with PBS served as
a negative control. After 20 h of incubation, the
samples were centrifuged at 2000=g for 10 min and
the absorbance of the supernatant was measured at
 .550 nm hemoglobin . The concentrations of ET-18-
 .  .OCH mM required to cause 5% hemolysis HI3 5
was calculated for each liposome composition inves-
tigated by interpolating between the concentrations
above and below 5% hemolysis.
2.5. Carboxyfluorescein permeability
Liposomes were prepared, as described above, in
 .  .the presence of 0.1 M 5 6 -carboxyfluorescein CF
 .Molecular Probes, Eugene, OR in PBS. CF contain-
ing liposomes were separated from non-liposome as-
sociated CF using a Sephadex G50 column at room
temperature. CF liposomes were then added to PBS
only, or PBS containing 0.5% serum equilibrated at
 .  .488C PBS or 378C PBS plus serum . Liposomes
were used within 30 min of separation. The final
ET-18-OCH concentration was between 20 and 10003
 .  .mM PBS or 1 mM PBS plus serum . The dye
efflux was monitored from the increased fluorescence
of CF, initially encapsulated within the liposomes at
the highly self-quenching concentration of 100 mM.
The fluorescence was monitored at 520 nm as a
function of time with excitation at 490 nm. 100%
release was determined after having added a suffi-
w xcient amount of Triton X-100 14 . Fluorescence
spectra were recorded with a photon counting
spectrofluorometer Photon Technology International,
.South Brunswick, NJ configured for a time based
measurement. The fluorescence was normalized as a
Table 1
Hemolytic activity of ET-18-OCH formulations3
 .  .Name Composition Molar ratio HI mM No. of experiments5
 .ET-18-OCH Ether lipid — 5.6"0.9 33
 .ELL-1 EPC:Chol:ET-18-OCH 4:3:3 21 13
 .ELL-2 Chol:DPPG:ET-18-OCH 5:3:2 72 13
 .ELL-3 DSPC:Chol:ET-18-OCH 4:3:3 20 13
 .ELL-4 EPC:Chol:DPPE-GA:ET-18-OCH 1:3:1:5 9 13
 .ELL-5 EPC:Chol:DPPE-GA:ET-18-OCH 3:3:1:3 14.1"3 23
 .ELL-6 EPC:Chol:DPPE-GA:ET-18-OCH 4:3:1:2 19.0 13
 .ELL-7 EPC:Chol:DPPE-GA:ET-18-OCH 5:3:1:1 33 13
 .ELL-8 EPC:Chol:POPE-GA:ET-18-OCH 1:3:1:5 14 13
 .ELL-9 EPC:Chol:POPE-GA:ET-18-OCH 3:3:1:3 20 13
 .ELL-10 EPC:Chol:POPE-GA:ET-18-OCH 4:3:1:2 31.5"2.3 23
 .ELL-11 EPC:Chol:POPE-GA:ET-18-OCH 5:3:1:1 31 13
 .ELL-12 DOPC:Chol:DOPE-GA:ET-18-OCH 4:3:1:2 250"25 53
 .ELL-13 DSPC:Chol:DPPE-GA:ET-18-OCH 1:3:1:5 9.0 13
 .ELL-14 DSPC:Chol:DPPE-GA:ET-18-OCH 3:3:1:3 10.5"1.8 23
 .ELL-15 DSPC:Chol:DPPE-GA:ET-18-OCH 4:3:1:2 18 13
 .ELL-16 DSPC:Chol:DPPE-GA:ET-18-OCH 5:3:1:1 20 13
 .ELL-20 DOPE:Chol:DOPE-GA:ET-18-OCH 4:3:1:2 640"60 23
 .ELL-30 EPC:Chol:DOPE-GA:ET-18-OCH 4:3:1:2 140 13
 .ELL-40 POPC:Chol:DOPE-GA:ET-18-OCH 4:3:1:2 45 13
 .ELL-28 DSPC:Chol:DOPE-GA:ET-18-OCH 4:3:1:2 22 13
 .Hemolysis: Lysis of human red blood cells RBC by free or liposomal ET-18-OCH was quantitated by hemoglobin release. Various3
 .  . concentrations 3 mM–2 mM of free or liposomal ET-18-OCH , or ET-18-OCH free plain liposomes, 1:1 vrv, blood:formulation,3 3
.  .serially diluted were incubated with 4% RBC washed in PBS, 3= at 378C for 20 h. Release of hemoglobin from an equal number of
RBC by hypotonic lysis in water was taken as 100% positive control; incubation with PBS served as a negative control. After 20 h of
incubation, samples were centrifuged at 2000=g for 10 min and the absorbance of the supernatant was measured at 550 nm. Each
 .formulation was tested in triplicate in each experiment. The mean concentrations required to cause 5% hemolysis HI were calculated5
by extrapolating between concentrations above and below 5% hemolysis.
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percentage of the total fluorescence, which was esti-
mated after disrupting the liposomes with Triton X-
100.
2.6. Monolayer studies
 .The mean molecular area per molecule MMAM
of ET-18-OCH formulations was determined using a3
Langmuir–Blodgett mini-trough equipped with a dual
barrier mechanism and a Wilhelmy balance KSV
.Instruments, Trumbull, Connecticut . ET-18-OCH3
formulations were prepared from powder and dis-
solved in a solvent system of hexane:ethanol, 9:1.
Mixtures were made to contain an overall lipid con-
centration of 1.5 mM which was verified by phos-
w xphate 15 assays. Chol was determined by HPLC as
described above. Monolayers were formed by drop-
wise addition of sample onto the aqueous surface 10
.mM HEPES, 150 mM NaCl buffer, pH 7.2 at the
center of the trough. The sample was added until the
surface pressure just started to rise above zero, at
which time the exact volume of sample added was
recorded. After waiting 3 min for solvent evaporation
and the monolayer to stabilize, the surface area was
reduced at a rate of 150 mm2rmin and surface
pressure recorded. The solution level was maintained
1 mm below the top edge of the trough to avoid
leakage; solution contact was maintained with the
 .barriers composed of Delrin due to their hydrophilic
nature. MMAMs were determined by extrapolating
the steepest portion of the pressure–area curve to the
value at zero surface pressure. For calculation of the
 .  .expected MMAM A , the values of MMAM A0
for the individual components were added propor-
tionately according to their mole fraction, that is,
A sx PA qx PA q . . . qx PA , where x is the0 1 1 2 2 n n
mole fraction of each component. All experiments
were done at 238C.
2.7. Association of ET-18-OCH with liposomes3
Continuous sucrose gradients from 2 to 20% and
.from 5 to 15% sucrose in water were made using a
 .Gradient Master BioComp, Fredericton, NB, Canada
at 15 rpm speed and 81.58C, using Beckman Ultra-
 .Clear centrifuge tubes 14=89 mm . 0.5 ml from
various ET-18-OCH -liposomal formulations in PBS3
were added at the top of the tube and centrifuged 20
.  .h at 200,000 g 58C . Fifty 250 ml fractions were
collected, starting from the top of the tubes, followed
by analysis by reverse-phase HPLC, using the method
previously described.
3. Results
3.1. Rationale for liposome compositions in˝estigated
The overall aim of this work was to identify
ET-18-OCH liposomes suitable for clinical investi-3
gation by the intravenous route.
Cholesterol is known to generally enhance the in
w xvivo stability of liposomes 16,17 and was recently
shown to pack favorably with ET-18-OCH in a3
w x1:1.5 mole ratio 10 . Thus ET-18-OCH :cholesterol3
assemblies were formulated with saturated and unsat-
urated lipids in order to assess the overall stability of
multicomponent systems in plasma. The role of the
phospholipid head group was investigated as the ge-
ometry and packing of lipids is known to play an
important role in liposome supramolecular assembly
w x18 . Most formulations included a negatively charged
w xcomponent to decrease aggregation 19 . In addition,
the inclusion of glutaric acid derivatized phospho-
 .lipids double negative charge was investigated be-
cause these derivatives have been shown to enhance
w xliposome circulation time 20 .
As the maximum incorporation of ET-18-OCH3
concomitant with the maintenance of other desirable
properties was of obvious importance, the effects of
variations in the mol% of ET-18-OCH in otherwise3
similar liposomes were also compared.
In initial experiments it was observed, at the light
microscope level, that ET-18-OCH readily formed3
extrudable non-aggregated liposomes with various
different liposome components. These liposomes were
 .used in the hemolysis experiments Table 1 .
3.2. Hemolysis
The liposome compositions investigated and the
results of hemolysis experiments are shown in Table
1. The HI was used as a comparative measure of5
minimal hemolytic activity. Free ET-18-OCH had3
an HI of 5–6 mM, less than the HI for all of the5 5
liposome formulations tested. Uncharged formula-
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Table 2
Characteristics of some ET-18-OCH -liposome preparations3
Name % Drug recovery Mean diameter"S.D. Captured volume
 .  .  .No. of experiments nm mlrmmol
 .ELL-20 100"15 3 98"19 n.d.
 .ELL-12 100"15 4 87"24 0.71
 .ELL-40 95"5 2 95"28 0.89
 .ELL-28 85"3 2 159"65 0.31
ET-18-OCH n.a. 11"1 n.a.3
 .Drug recovery % drug retained during liposome preparation , mean diameter and capture volume of various ET-18-OCH liposomal3
formulations. The chemical composition of the formulations was X:Chol:DOPE-GA:ET-18-OCH s4:3:1:2 mol, where X is DOPE for3
ELL-20, DOPC for ELL-12, POPC for ELL-28 and DSPC for ELL-28.
n.d.snot determined.
n.a.snot applicable.
 .  .Fig. 1. Freeze fracture electron micrographs of ELL-12 A and ELL-20 B , where the chemical compositions were X:Chol:DOPE-
GA:ET-18-OCH s4:3:1:2 mol and X was DOPC for ELL-12 and DOPE for ELL-20. The bar represents 300 nm.3
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 .tions ELL-1 and -3 attenuated hemolysis about
three fold compared to free ET-18-OCH . When the3
series ELL-4–7, 8–11 and 13–16 were inspected it
was seen that decreasing the mol% ET-18-OCH3
increased the attenuation of hemolysis. For series
8–11 and 13–16 the attenuation of hemolysis was
similar between 10 and 20 mol% ET-18-OCH . The3
maximum attenuation of hemolysis was somewhat
less for a negatively charged saturated phospholipid
 .series 13–16 than for the two unsaturated nega-
 .tively charged phospholipid series 4–7 and 8–11 .
ELL-12 in which EPC was replaced with DOPC,
was less hemolytic than any of the EPC formulations.
Liposomes prepared using 20 mol% dioleoylphos-
 .phatidylethanolamine DOPE instead of DOPC
 .ELL-20 were even less hemolytic than ELL-12.
Other formulations were inferior to ELL-12 or ELL-
20 with respect to attenuation of hemolysis, including
ELL-2 which was composed of 50 mol% Chol plus
DPPG as a negatively charged component. The re-
sults suggest that both the nature of the phospholipid
head group and the overall combined molecular shape
of the multi-component system is important for effi-
cient attenuation of hemolysis.
3.3. ET-18-OCH -liposome a˝idity3
Some ET-18-OCH liposome preparations were3
characterized by different methods to determine the
affinity of ET-18-OCH to form liposomes with vari-3
ous lipids. A summary of the results is shown in
Table 2. For all formulations, with the exception of
ELL-28, no significant ET-18-OCH loss occurred3
 .Fig. 2. Time course of carboxyfluorescein CF release from
ET-18-OCH liposomal formulations in PBS at 488C. The chem-3
ical compositions of the formulations were X:Chol:DOPE-
GA:ET-18-OCH s4:3:1:2 mol, where X is DOPC for ELL-12,3
DOPE for ELL-20, EPC for ELL-30 and DSPC for ELL-28. The
liposomes were diluted 100 fold into 488C PBS at the beginning
of each experiment. The dye efflux was monitored as a function
of time, by the increased fluorescence of CF, initially encapsu-
lated within the liposomes at the highly self-quenching concentra-
tion of 100 mM. Excitation was and 490 nm and fluorescence
was detected at 520 nm. Leakage is expressed as an increase in
CF fluorescence relative to the total CF present after disrupting
the liposomes with Triton X-100.
during preparation and extrusion. After extrusion the
size distributions of the various preparations were
Gaussian, consistent with the formation of a single
population of liposomes, although ELL-28 was again
an exception. All formulations evaluated had cap-
tured volumes ranging from 0.31 to 1.0 mlrmmol.
For ELL-12 there was no significant change in the
chemical composition or liposomal size distribution
over a 3 month period.
Fig. 1 shows freeze fracture electron micrographs
Table 3
Stability of ET-18-OCH liposomal formulations in 0.5% serum at 378C3
1Name Composition t 2
 .  .mol% min
ELL-20 DOPE:CHOL:DOPE-GA:ET-18-OCH , 4:3:1:2 10803
ELL-12 DOPC:CHOL:DOPE-GA:ET-18-OCH , 4:3:1:2 2603
ELL-30 EPC:CHOL:DOPE-GA:ET-18-OCH , 4:3:1:2 4.73
ELL-40 POPC:CHOL:DOPE-GA:ET-18-OCH , 4:3:1:2 0.423
ELL-28 DSPC:CHOL:DOPE-GA:ET-18-OCH , 4:3:1:2 0.133
1Comparison of the t of ET-18-OCH liposomal formulations in the presence of 0.5% serum. Liposomes were diluted 500 fold into32
preheated 378C PBS, containing 0.5% serum at the beginning of each experiment. Dye efflux was monitored by increase of fluorescence
at 520 nm using excitation wavelength 490 nm and the time required for 50% of carboxyfluorescein entrapped in the liposomes to leak to
1 .the external environment was calculated t . 100% release was determined after having added sufficient amount of Triton X-1002
resulting in disruption of liposomes and release of entrapped dye.
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 .Fig. 3. Comparison of the hemolytic activity Table 1 and
 .carboxyfluorescein leakage Fig. 2 in ET-18-OCH liposomes.3
The CF release is expressed as a percentage of the total after 25
min incubation with PBS at 488C.
 .  .of ELL-12 Fig. 1a and ELL-20 Fig. 1b prepara-
tions. In both cases typical spherical liposome struc-
tures of relatively uniform size, around 100 nm, can
be seen. Most of the liposomes were unilamellar with
some multilamellar structures visible. There was little
visible aggregation in ELL-12 although it was possi-
ble there was more aggregation in ELL-20.
3.4. Carboxyfluorescein permeability
CF has been widely used as a sensitive indicator
w xfor liposome permeability 21 and Fig. 2 shows there
was a time dependent permeation of CF from ET-18-
Table 4
 .Mean molecular area per molecule MMAM for monolayers of
ELL lipid mixtures with or without ET-18-OCH present3
b
˚ .MMAM A rmolecule
aFormulation Expected Actual Difference
ELL-12 72.0 51.3 y20.7
ELL-12 without ET-18-OCH 70.0 60.3 y9.73
ELL-20 71.8 53.3 y18.5
ELL-20 without ET-18-OCH 70.2 58.7 y11.53
ELL-40 71.9 49.3 y22.6
ELL-40 without ET-18-OCH 69.5 57.7 y11.83
a Lipid molar ratios for formulations without ET-18-OCH were3
4:3:1 phospholipidrCholrDOPE-GA.
b Expected MMAM is the value calculated for the mixtures based
on simple additivity of the MMAM for individual components.
Actual MMAM were those values determined experimentally as
outlined in Section 2.
OCH liposomes in buffer at 488C. This temperature3
was used because permeation at 378C was slow. It
can be seen that the DOPC and DOPE formulations
 .ELL-12 and ELL-20 were the least permeable of
the formulations tested, with less than 6% CF leaking
out in 25 min compared to over 27% for the DSPC
containing ELL-28 formulation. Table 3 shows that
ELL-20, followed by ELL-12, released CF at the
slowest rates in 0.5% serum. Fig. 3 is a plot of CF
leakage versus hemolytic activity in buffer. Formula-
tions with slower CF release rates were less hemolytic,
possibly reflecting tighter lipid packing.
Fig. 4. Homogeneity of DOPC and DSPC based ET-18-OCH3
 .  .liposomal formulations. ET-18-OCH , Chol and DOPC A of3
 .DSPC for 4B concentrations present in fractions collected after
density gradient centrifugation of ET-18-OCH liposomal formu-3
lations. The chemical compositions of the formulations were
X:Chol:DOPE-GA:ET-18-OCH s 4:3:1:2 mol, where X is3
 .  .DOPC A and DSPC B . The gradient was 2 to 20% sucrose
 .  .A and from 5 to 15% sucrose B . Formulations were cen-
trifuged for 20 h at 200,000= g at 58C. Fifty fractions were
collected and analyzed by reverse phase HPLC Inertsil ODS2
.150=4.6 mm column with an evaporative light scattering detec-
tor using 4% water in methanol as a mobile phase. The insert in
 .B is an enlargement of the 0–10 fraction section on the main
chart. The symbols used are the same as in the main chart.
( )E. Mayhew et al.rBiochimica et Biophysica Acta 1329 1997 139–148146
3.5. Monolayer studies
As complementary packing between lipids facili-
w xtates the formation of lamellar structures 18,22 it
was thought possible that complementary packing
between ET-18-OCH and other lipids could play a3
role in reducing the transfer of ET-18-OCH from3
liposomes to red cell membranes. To assess the de-
gree of shape complementarity for the formulations
used here, we measured the mean molecular area per
 .molecule MMAM for monolayers of lipid mixtures
spread upon a Langmuir trough. Table 4 shows the
MMAM of the lipid components of three ether lipid
 .liposome formulations with four component and
 .without three component the inclusion of ET-18-
OCH . It can be seen that MMAM values with3
ET-18-OCH present were significantly less 19–233
˚
2 .A per molecule than those predicted based on sim-
ple additivity of the individual components see Sec-
.tion 2 for details . These reductions in MMAM were
consistent with a significant degree of shape comple-
w xmentarity 22 .
3.6. Homogeneity of ET-18-OCH association with3
liposomes
ET-18-OCH liposome formulations with large3
differences in the HI 5 value were characterized for
 .Fig. 5. Calculated CholrET-18-OCH A and B, solid triangles3
 .  .and DOPCrET-18-OCH A or DSPCrET-18-OCH B molar3 3
ratios of fractions collected after density gradient centrifugation
 .  .of DOPC A or DSPC B based ET-18-OCH liposomal formu-3
 .lations see legend to Fig. 4 .
homogeneity using density gradient centrifugation.
Fig. 4 shows that most of the lipids from the DOPC
 .formulation ELL12 were found towards the top of
 .the gradient fractions 1–15 whereas lipids from the
 .DSPC formulation ELL-28 were found in fractions
20 and higher. It can also be seen in Fig. 5A that the
values for the individual components paralleled one
another for the DOPC formulation whereas they did
not for the DSPC formulation. Fig. 5B shows that the
DOPCrET-18-OCH and CholrET-18-OCH mole3 3
ratios remained constant in all fractions in ELL-12
whereas the CholrET-18-OCH ratio was increased3
in fractions 24–30 and DSPCrET-18-OCH was3
increased in fractions 35–40 for ELL-28. The results
indicate that ELL-12 is composed of a much more
compositionally homogeneous population of lipo-
somes compared to ELL-28. In another experiment,
we found that ELL-20, another non-hemolytic formu-
lation, was as homogenous as ELL-12.
4. Discussion
The results show that association of ET-18-OCH3
with liposomes attenuated hemolysis in a composi-
tion dependent manner.
We used a hemolysis assay to compare different
liposome formulations because we believed hemoly-
sis reduction by liposome entrapment to be a useful
indicator of liposome stability. ET-18-OCH forms3
micelles in water above its critical micellar concen-
w xtration, which is approximately 0.5 mM 23 , and
hemolysis occurs at concentrations above this value
probably as a result of critical accumulations in RBC
membranes. The attenuation of hemolysis may be due
to a decrease in the amount of solution phase ET-18-
OCH , reflecting its stable association with liposome3
membranes. However, we cannot rule out that hemol-
ysis could take place as a result of the transfer of
ET-18-OCH directly to RBC through processes me-3
diated by liposome-RBC collision.
A much greater attenuation of hemolysis occurred
using DOPC or DOPE di-C18, unsaturated fatty acid
.chains as the major neutral phospholipid compo-
nents, rather than DSPC di-C18, saturated fatty acid
. chains . However EPC mixed C16 and C18, satu-
.rated and unsaturated fatty acid chains attenuated
hemolysis at least as well as DSPC suggesting that
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fatty acid chain saturation is not the only factor
involved in hemolysis attenuation. Hemolysis attenu-
ation was also dependent on negatively charged phos-
pholipid components in otherwise similar liposomes.
 .DOPE-GA di-C18 attenuated hemolysis more than
 .  .POPE-GA C16, C18 or DPPE-GA di-C16 in EPC
liposomes suggesting that matching neutral or nega-
tively charged C18 phospholipid fatty acid chains
form the most stable, least hemolytic, liposomes in
association with ET-18-OCH , which itself has a3
single C18 fatty acid chain. The presence of DOPE
attenuated hemolysis more than DOPC. This suggests
that the phospholipid head group and the overall
macromolecular structure assembly plays an impor-
tant role in stable liposome architecture. The Lang-
muir trough data strongly supported the hypothesis
that in two component systems the more cone-like
DOPE packs better with the inverted cone-like ET-
w x18-OCH , than with the more cylindrical DOPC 22 .3
The data presented in this report also show that when
ET-18-OCH was included in multi-component3
DOPE or DOPC liposomes, the mean molecular area
decreased more than would be expected. Thus, lipids
pack tighter in ET-18-OCH liposomes. The rate of3
CF permeation from ET-18-OCH liposomes may3
also be related to the packing of lipid molecules in
the lipid bilayers because CF a charged water solu-
.ble compound cannot permeate easily through well
packed lipid bilayers when it is entrapped in the
w xaqueous space of liposomes 21 .
Alkyl phospholipid derivatives have been investi-
gated previously in order to elucidate their physico–
w xchemical properties 24,25 and to elucidate their
interactions with model membranes including phos-
w xpholipids and liposomes 26–28 . In addition, ether
lipids other than ET-18-OCH have been entrapped3
in liposomes and investigated for their biological
w xproperties 29,30 . For example, ET-18-OCH was3
entrapped in PC:Chol liposomes to a maximum of 10
mol% and it was shown to inhibit 3H-thymidine
w xincorporation in L1210 and L929 cells in vitro 9 . In
w xa subsequent report 31 , the same group, using the
same type of liposome, reported that ET-18-OCH3
liposomes could activate macrophages. However, no
systematic exploration of the effects of modification
of liposome composition in in vitro biological sys-
tems has been reported, nor have any in vivo studies
accomplished. Some investigations of the role of
liposome composition, including inclusion of nega-
tively charged lipids, on in vitro cytotoxicity and
anti-tumor effects were accomplished using other
w xether lipids 9 , but again no systematic investigations
w xhave been described. Recent reports 30,32 describe
 .results using hexadecylphosphocholine Miltefosine
entrapped in small unilamellar vesicles composed of
dicetylphosphate:Chol:HPC in a 1:10:10 molar ratio.
Reduced hemolysis by liposome formulations was
observed.
Although no direct extrapolation can be made
between the studies reported herein and in vivo ef-
fects of ET-18-OCH , it is noteworthy that in animal3
and clinical studies hemolysis is a significant toxicity
and may be dose limiting in some circumstances
w x2,3 . It is therefore possible that liposome formula-
tions of ET-18-OCH which have been shown to3
have greatly attenuated hemolysis in vitro may also
be less hemolytic in vivo. Formulations where phos-
pholipids pack efficiently with ET-18-OCH , such as3
ELL-12 or 20, which are relatively non-hemolytic
and non-permeable in buffer and serum, are therefore
prime candidates for investigation as in vivo delivery
w xsystems for ET-18-OCH 33 .3
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